Nutex Health (NUTX) Cash & Equivalents (2010 - 2026)

Nutex Health (NUTX) has 17 years of Cash & Equivalents data on file, last reported at $207.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 144.72% year-over-year to $207.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $207.3 million (up 144.72% YoY) and the FY2025 annual result came in at $185.6 million, up 356.63% from the prior year.
• Cash & Equivalents grew to $207.3 million in Q1 2026 per NUTX's latest filing, from $185.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $207.3 million in Q1 2026, with the low at $3.3 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $66.8 million, with a median of $40.6 million recorded in 2024.
• The widest YoY moves for Cash & Equivalents: up 909.53% in 2023, down 35.77% in 2023.
• Nutex Health's Cash & Equivalents stood at $34.3 million in 2022, then tumbled by 35.77% to $22.0 million in 2023, then surged by 84.71% to $40.6 million in 2024, then surged by 356.63% to $185.6 million in 2025, then grew by 11.73% to $207.3 million in 2026.
• Business Quant data shows NUTX's Cash & Equivalents at $207.3 million in Q1 2026, $185.6 million in Q4 2025, and $166.0 million in Q3 2025.